Patent Application
20140194308
The present invention relates to use of myelin basic protein as a novel genetic factor for rheumatoid arthritis.
Rheumatoid arthritis (hereinafter, abbreviated to “RA”) is a systemic disease associated with various symptoms including joint pain, dysfunction and deformity, as well as interstitial pneumonia and scleritis. RA is the most common cause of adult chronic inflammatory arthritis, affecting 0.5-1% of the adult population worldwide. Both genetic and environmental factors have been implicated in the development of RA (Non-Patent Documents Nos. 1 and 2). Although the polymorphisms of HLA as a human major histocompatibility antigen are the strongest genetic factors for RA, these can account for only 30-50% of the total genetic factors (Non-Patent Document No. 3). To date, various novel genetic factors have been identified by genome-wide, comprehensive analyses (GWAS: genome-wide association study) in case-control groups using markers (mainly SNPs) (Non-Patent Documents Nos. 4-21). However, even with all the novel genetic factors being considered together, only a small part of the genetic factors for RA can be explained. Besides, ethnic specificity is very strong in these genetic factors and many of them are risk factors limited to Europeans and Americans while equally many are risk factors limited to Asians (Non-Patent Documents Nos. 22-26, 12 and 17).
Conventionally, detection of autoantibodies in sera from RA patients has been performed by ELISA techniques, among which anti-CCP antibody detection ELISA is the most common method used today. Anti-CCP antibodies are autoantibodies excellent in both sensitivity and specificity to RA patients (Non-Patent Document Nos. 27 and 28). However, they are antibodies not against a specific protein but against a plurality of citrullinated proteins and, moreover, no antigens have been identified for commercialized anti-CCP antibodies. Further, few autoantibodies other than anti-CCP antibody have so far been known to be useful in diagnosing anti-CCP antibody-negative RA patients.
It is believed that a large number of RA genetic factors in Japanese are yet to be found. Under the circumstances, the present invention aims at searching for novel genetic factors for RA by performing a large-scale GWAS in Japanese.
It is another object of the present invention to find out autoantibodies other than anti-CCP antibody which are useful in diagnosing anti-CCP antibody-negative RA patients.
RA is a systemic disease that is the most common cause of adult chronic inflammatory arthritis. Although several genetic factors have been identified as risk factors for RA, they account for only a small part of the whole group of predicted genetic factors. The present inventors have conducted a large-scale case-control study in Japanese using a total of 225,079 single nucleotide polymorphisms (SNPs) as markers in an attempt to identify novel genetic risk factors for RA. The case-control study consisted of two sample sets for screening and two sample sets for result confirmation. The numbers of samples (RA patients vs healthy controls) were as follows: 658 cases vs 934 controls and 332 cases vs 307 controls in the screening sets, and 874 cases vs 855 controls and 1264 cases vs 948 controls in the result confirmation sets. As a result, the present inventors have found that a SNP (rs2000811) in intron 2 of myelin basic protein (MBP) gene located on the long arm of chromosome 18 is a novel risk factor for RA. A p value in meta-analysis was 2.7*10{circumflex over (0)}̂−8 and an odds ratio was 1.23 (with a 95% confidence interval of 1.14-1.32). The expression of MBP gene correlated with the SNP in intron 2. Further, the inventors have found that MBP protein is highly expressed in the synovial membrane of RA patients which is the main target of RA inflammation. The titers of autoantibodies to human brain-derived MBP protein (anti-MBP antibodies) in sera were investigated by ELISA, revealing that they were significantly higher in the group of RA patients than in the group of healthy people and in the group of patients with other connective tissue diseases (p value <0.001). In order to more closely investigate the protein to be recognized by anti-MBP antibodies, the present inventors prepared a recombinant MBP protein and citrullinated it in vitro. Using the citrullinated recombinant MBP protein and non-citrullinated recombinant MBP protein, correlations of antibody titers were examined by ELISA. As a result, it was found that antibodies reacting with human brain-derived MBP strongly correlated with citrullinated MBP. In conclusion, the present inventors have identified myelin basic protein as a novel genetic factor for RA by combining genetic methods with immunological methods.
A summary of the present invention is as described below.
According to the present invention, the association of rs2000811 with RA has been elucidated.
Further, according to the present invention, it was also shown that anti-MBP antibodies are RA markers. Anti-MBP antibodies are useful in diagnosis because they are not only highly specific but also test positive to some extent even in anti-CCP antibody- or rheumatoid factor-negative patients who have been difficult to diagnose.
The present specification encompasses the contents disclosed in the specification and/or drawings of Japanese Patent Application No. 2011-95625 based on which the present application claims priority.
[
Results of Association Analyses of MBP Gene Locus at Chromosome 18q23
p values obtained from association analyses in SNPs located between rs470131 and rs2717096 are plotted in logarithm. Arrows indicate the orientations of genes. Red circle indicates the results of 4 sample sets for rs2000811. Blue dots indicate the results of 2 sample sets. Triangles show the results of linkage disequilibrium.
[
Allele-Specific MBP Transcription by Allele-Specific Real-Time PCR
Amounts of mRNA precursors immediately after transcription from MBP gene were compared between alleles of rs2000811. The analysis was performed with RNA extracted from cells with hetropolymorphism. DNA from those cells was used as control, on the assumption that it was a 1:1 mixture of the two alleles.
[
Immunohistochemistry of the MBP Protein in Human Synovial Membrane Using Monoclonal Anti-MBP Antibody
A) RA patient-derived synovial membrane strongly expressed MBP protein along the synovial lining layer. B) MBP protein was not expressed in osteoarthritis patients. C) The expression of MBP protein in RA patients' synovial membrane was weak around follicules of infiltrated lymphocytes. D) MBP protein was localized in the plasma membrane of synoviocytes.
[
Quantification of Circulating Anti-MBP Antibodies
A) Comparison between healthy controls, RA patients, and patients with other connective tissue diseases. *** indicates p values smaller than 0.001. B) Correlation of autoantibody titers between human brain-derived MBP protein and recombinant MBP protein. C) Correlation of autoantibody titers between human brain-derived MBP protein and citrullinated recombinant MBP protein.
[
QQ Plot Showing Comparison Between Observed and Expected p-Values
A) Vertical and horizontal axes indicate observed and expected p-values, respectively. B) Both p-values are expressed in logarithm.
The analysis using the genomic control method for determining the presence or absence of population stratification showed no significant effect of population stratification.
[
Linkage Disequilibrium (LD) Block of the 156-kb Region Comprising MBP Gene
LD map was generated with Haploview software on SNPs with allele frequencies between 0.05 and 0.95.
[
Allelic Difference in MBP Transcription
Human B-lymphoblastoid cell lines immortalized by EBV were obtained from PSC. RNA was extracted for each genotype of rs2000811 and reverse-transcribed to cDNA (CC type: 50 persons; TC type: 50 persons; TT type: 49 persons). The transcription of MBP (Hs00921943-ml, Applied Biosystems Inc., Foster City, Calif.) was quantified by real time PCR using β-glucuronidase (Hs99999908_ml, Applied Biosystems Inc., Foster City, Calif.) as an endogenous reference. The ΔΔCT method was used to calculate transcription levels, and Jonckheere-Terpstra test was used for the analysis.
Hereinbelow, the present invention will be described in detail.
The present invention provides a method of testing for rheumatoid arthritis, comprising detecting an autoantibody to myelin basic protein in a biological sample from a subject.
In the present specification, the expression “testing for rheumatoid arthritis” encompasses those tests for judging whether the risk to develop rheumatoid arthritis (RA) is high or low in a subject and, when the subject is already affected by RA, those tests for conducting definitive diagnosis of RA.
Specific examples of biological samples from subjects include, but are not limited to, blood (e.g., whole blood, serum, plasma, and extracellular fluid from plasma exchange), skin, oral mucosa, tissue or cell collected or excised by surgery, and body fluid collected for such purposes as testing (e.g., saliva, lymph, respiratory mucosa, sperm, sweat, and urine). As a biological sample, serum is preferable.
Myelin basic protein (MIM: 159430; OMIM database) is a protein consisting of 169 amino acids with a molecular weight of about 18000. MBP is a major constituent of the myelin sheath of neuronal cells. It is assumed that MBP is associated with the neurodegenerative disease multiple sclerosis (hereinafter, abbreviated to “MS”), because i) autoantibodies to MBP are found in blood and spinal fluid from MS patients and ii) injection of MBP to mice induces a condition similar to MS. On the other hand, no mutation in MBP gene has been found in MS patients. A number of transcription variants are transcribed from MBP gene and they are translated into proteins, which are roughly classified into classic MBP that constitutes the myelin sheath and Golli MBP that is expressed in oligodendrocytes and peripheral lymphocytes. Although the function of Golli MBP is largely unknown, it is suggested that Golli MBP may be involved in the regulation of intracellular Ca concentration and also involved in the differentiation of immune cells.
In the test method of the present invention, an autoantibody to MBP is detected in a biological sample from a subject.
For detecting autoantibodies to MBP, ELISA and Western blotting is preferably used. The MBP used for quantifying autoantibodies is preferably derived from human, and more preferably derived from human brain. MBP may be extracted from in vivo samples by biochemical techniques or may be prepared by genetic recombination techniques. Alternatively, a commercial MBP such as recombinant human MBP (Genscript, Piscataway, N.J.) may be used. MBP may or may not be citrullinated. The citrullination of MBP may be performed by known methods using PAD (Lundberg K, Kinloch A, Fisher B A, Wegner N, Wait R, et al. (2008) Antibodies to citrullinated alpha-enolase peptide 1 are specific for rheumatoid arthritis and cross-react with bacterial enolase. Arthritis Rheum 58: 3009-3019).
When the concentration of autoantibody to MBP is 2.74 AU, it can be judged that the subject is very likely to develop RA or is already affected by RA. Alternatively, when the concentration of autoantibody to MBP is 2.16 AU or more, the result is regarded as positive and the final judgment of RA may be made after taking into consideration the results from other test methods (e.g., the rheumatoid factor (RF) test, the anti-CCP antibody measuring method (an autoantibody measuring method using an antigen that is an artificially circularized, citrullinated peptide), clinical observation, etc.).
Autoantibodies to MBP are useful as RA diagnostic markers.
The subject of the test method according to the present invention is a patient who is suspected of developing RA or being affected by RA; if desired, the subject may be any human who has a conceivable risk to develop RA.
Further, the present invention provides a test kit for RA, comprising MBP.
The MBP is preferably derived from human, and more preferably derived from human brain. MBP may be extracted from in vivo samples by biochemical techniques or may be prepared by genetic recombination techniques. Alternatively, a commercial MBP such as recombinant human MBP (Genscript, Piscataway, N.J.) may be used. MBP may or may not be citrullinated. The citrullination of MBP may be performed by known methods using PAD (Lundberg K, Kinloch A, Fisher B A, Wegner N, Wait R, et al. (2008) Antibodies to citrullinated alpha-enolase peptide 1 are specific for rheumatoid arthritis and cross-react with bacterial enolase. Arthritis Rheum 58: 3009-3019). MBP protein extracted from in vivo samples by biochemical techniques, recombinant MBP protein, or citrullinated forms of these proteins is preferably bound to ELISA plates.
The test kit of the present invention may further comprise enzyme-labeled antibodies (e.g., alkaline phosphatase-labeled anti-human IgG polyclonal antibody (goat)), substrate solutions for enzymes (e.g., BCIP/NBT), reaction buffers, washing buffers, quenching solutions, standard solutions, positive controls, negative controls, and manuals describing criteria for judgment of RA, operational procedures, etc.
Further, the present invention provides a method of judging the risk to develop RA, comprising identifying the single nucleotide polymorphism of a nucleotide present in the MBP gene of a subject or identifying the single nucleotide polymorphism of a nucleotide that is in linkage disequilibrium with the first mentioned nucleotide. The single nucleotide polymorphism of a nucleotide present in the MBP gene is preferably rs2000811 in the SNP database of the National Center for Biotechnology Information (NCBI), the United States. When the nucleotide of the single polymorphism of rs2000811 is T in at least one allele or when the genotype of the single polymorphism of rs2000811 is C/T or T/T, susceptibility to rheumatoid arthritis can be judged high.
The nucleotide of the polymorphic site of rs2000811 may be represented as the 1102nd nucleotide (y=C/T) in the nucleotide sequence as shown in SEQ ID NO: 1. The nucleotide sequence as shown in SEQ ID NO: 1 exists in the second intron of MBP gene on human chromosome 18.
The polymorphism which is in linkage disequilibrium with rs2000811 is preferably a polymorphism in the LD blocks of rs2000811.
When the D′ value between SNPs is large, the SNPs are believed to be in linkage disequilibrium (Barrett J C, Fry B, Mailer J, Daly M J. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005; 21(2):263-265; Gabriel S B, Schaffner S F, Nguyen H, et al. The structure of haplotype blocks in the human genome. Science. 2002; 296(5576):2225-2229). Therefore, the polymorphism in linkage disequilibrium with rs2000811 is, for example, such a polymorphism that the D′ value between rs2000811 and itself is more than 0.8.
LD blocks may be determined with Haploview software (Barrett J C, Fry B, Maller J, Daly M J. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005; 21(2):263-265) by the method of Gabriel et al. (Gabriel S B, Schaffner S F, Nguyen H, et al. The structure of haplotype blocks in the human genome. Science. 2002; 296(5576):2225-2229).
As an example of polymorphisms in the LD blocks of rs2000811, rs9958028 may be given. When the nucleotide of the single nucleotide polymorphism of rs9958028 is G in at least one allele, or when the genotype of the single nucleotide polymorphism of rs9958028 is A/G or G/G, susceptibility to RA can be judged high.
The nucleotide of the polymorphic site of rs9958028 may be represented as the 501st nucleotide (r=A/G) in the nucleotide sequence as shown in SEQ ID NO: 2. The nucleotide sequence as shown in SEQ ID NO: 2 exists in the second intron of MBP gene on human chromosome 18.
In the present specification, single nucleotide polymorphism (SNP) is expressed in rs number which is a reference SNP ID number assigned in dbSNP (the SNP database of NCBI). The position of nucleotide is based on build36 which is a genome database of NCBI.
The SNP to be identified may be rs2000811 alone or a combination of rs2000811 and other SNP. Specific examples of other SNP include, but are not limited to, rs9958028.
Identification of the nucleotide of the polymorphic site (i.e., determination of nucleotide species) may be performed by known methods for single nucleotide polymorphism analysis. Specific examples of such methods include, but are not limited to, direct sequencing, the RFLP method, the PCR-SSCP method, allele-specific oligonucleotide hybridization, TaqMan PCR, the invader method, the MALDI-TOF/MS method, the molecular beacon method, RCA, the UCAN method, and nucleic acid hybridization using DNA chips or DNA microarrays.
For identification of the nucleotide of the polymorphic site, genomic DNA may be extracted from a biological sample of a subject. Examples of biological samples include, but are not limited to, subject's blood (e.g., whole blood, serum, plasma, and extracellular fluid from plasma exchange), skin, oral mucosa, tissue or cell collected or excised by surgery, and body fluid collected for such purposes as testing (e.g., saliva, lymph, respiratory mucosa, sperm, sweat, and urine). As a biological sample, plasma is preferable. It is possible to extract genomic DNA from a biological sample using a commercial DNA extraction kit. Subsequently, if necessary, DNA fragments comprising a polymorphic site are isolated. This isolation of DNA fragments may typically be performed by PCR using primers capable of hybridizing to the DNA fragment comprising a polymorphic site, with genomic DNA or RNA being used as a template.
The present invention also provides a kit for judging the risk to develop rheumatoid arthritis, comprising nucleic acid probes and/or nucleic acid primers capable of detecting the single nucleotide polymorphism of a nucleotide present in the myelin basic protein gene of a subject or the single nucleotide polymorphism of a nucleotide that is in linkage disequilibrium with the first mentioned nucleotide.
The single nucleotide polymorphism of a nucleotide present in the myelin basic protein gene of a subject and the single nucleotide polymorphism of a nucleotide that is in linkage disequilibrium with the first mentioned nucleotide are as described above.
The primers and/or probes contained in the kit of the present invention are preferably oligonucleotides with a length of at least 15 nucleotides. When oligonucleotides are to be used as primers, their length is usually 15 by to 100 by and preferably 17 by to 30 bp. Primers are not particularly limited as long as they are capable of amplifying at least a part of a DNA fragment containing the above-described polymorphic site. The length of DNA fragment which can be amplified with primers is usually 15-1000 bp, preferably 20-500 bp, and more preferably 20-200 bp. When oligonucleotides are to be used as probes, their length is usually 15-500 by and preferably 30-500 bp. Probes are not particularly limited as long as they are capable of hybridizing to a DNA fragment containing the above-described polymorphic site. The length of DNA fragment to which probes can hybridize is usually 16-500 bp, preferably 20-200 bp, and more preferably 20-500 bp. Any person skilled in the art could appropriately design such primers and probes based on nucleotide sequence information about DNA regions surrounding the polymorphic site. Such primers and/or probed may be labeled in advance (with radioisotope, fluorescent dye or the like). Probes may be immobilized on a solid phase such as a substrate.
The kit of the present invention may further comprise hybridization reagents, agents for detecting the label of primers and/or probes, buffers, manuals describing criteria for judgment of the risk to develop RA and the method of using the kit, and ELISA plates to which MBP protein extracted from in vivo sample by biochemical techniques, recombinant MBP protein, or citrullinated forms of such MBP proteins are bound.
Further, the present invention provides a method of screening for a substance effective as a prophylactic and/or therapeutic for rheumatoid arthritis, comprising adding a test substance to a myelin basic protein gene-expressing cell and then determining the expression level of the myelin basic protein gene or the gene product thereof.
The myelin basic protein gene-expressing cell may be derived from any organism as long as the expression of myelin basic protein can be observed at the protein level or the nucleic acid level and examples include, but are not limited to, cells derived from mammals such as human, pig, monkey, chimpanzee, dog, cattle, rabbit, rat, and mouse. It is preferable to use human-derived cells (e.g., neuronal cells).
The test substance may be any substance. Examples of the test substance include, but are not limited to, proteins, peptides, vitamins, hormones, polysaccharides, oligosaccharides, monosaccharides, low molecular weight compounds, nucleic acids (DNA, RNA, oligonucleotide, mononucleotide, etc.), lipids, natural compounds other than those listed above, synthetic compounds, plant extracts, fractions from plant extracts, and mixtures thereof.
Quantification of the expression level of MBP gene or the gene product thereof may be performed by determining the amount of the transcription product of MBP gene or the activity of the transcription product.
The amount of the transcription product may be determined by performing quantitative PCR analysis on the cDNA, as obtained through reverse transcription of RNA in the sample, using a primer set for amplifying an MBP gene-specific sequence. If applicable, Northern blotting with a probe specific to MBP gene may be performed. Alternatively, the transcription product may be quantified by using DNA chips.
The amount and/or activity of the transcription product of MBP gene can typically be detected by immunoassay, quantification of enzyme activities, or binding assay. These assays may be performed by using a label (e.g. enzymatic, fluorescent, radioactive, magnetic, or luminescent) that binds to anti-MBP antibody or a secondary antibody binding to anti-MBP antibody and determining the amount of binding between the above-described translation product and anti-MBP antibody.
Hereinbelow, the present invention will be described in more detail with reference to the following Example. However, the present invention is not limited to this Example.
Four case-control sample sets (collections) were used. Two collections were used in GWAS for screening, and the other two were used for confirmation of the screening results. The number of samples (RA patients vs healthy controls) in each collection was as follows: 1st collection for screening: 658 cases vs 934 controls; 2nd collection for screening: 332 cases vs 307 controls; 3rd collection for result confirmation: 874 cases vs 855 controls; and 4th collection for result confirmation: 1264 cases vs 948 controls (Table 2). With respect to the 934 healthy controls in the 1st collection, data publicly disclosed in JSNP were used. The samples were plasma samples taken from patients in Kyoto University, Dohgo Spa Hospital, Tokyo Women's Medical University, The University of Tokyo, Sagamihara National Hospital, and Aichi Cancer Center; also used were cell lines obtained from PSC. All patients satisfied the criteria of the ACR. Studies were approved by the ethical committees of relevant research organizations.
For GWAS, Infinium chips of Illumina Inc. were used. With four different chips (Human-Hap300, CNV370-Duo, HumanHap550, and Human610-Quad), the present inventors focused on 277420 SNPs common to these four chips. DNA samples removed from analyses were with a call rate smaller than 90%, showed kinship with other samples, did not fall into the Japanese cluster on principal component analysis, and were suspected of possible contamination with other DNA. SNPs with a call rate greater than 95% and a minor allele frequency greater than 5% were selected. As a result, the numbers of remaining samples were 643 vs 934 in the 1st collection and 327 vs 297 in the 2nd collection. Regarding the SNP markers, a total of 225,079 markers were obtained. Association analysis was performed on each marker in the 1st and 2nd collections independently. Those SNPs that showed p<0.005 in both collections and p-values smaller than 0.0001 in meta-analysis of the 1st and 2nd collections were selected. Except for those regions where association is known in Japanese RA cases, a SNP with the smallest p-value in meta-analysis was selected from a plurality of markers that were found in one LD block. For the thus selected SNPs, association was confirmed in the 3rd and 4th collections.
After finding association of MBP region, the present inventors performed sequencing of the promoter region and the amino acid-encoding exon regions of the MBP gene in 84 healthy control DNAs.
Genome sequence alignment of 14 placental mammals was obtained from a publicly disclosed database. Transcriptional regulatory elements were searched for in regions comprising SNPs of interest.
Quantification of allele-specific MBP transcription was performed as already known (e.g., Suzuki A, Yamada R, Kochi Y, Sawada T, Okada Y, et al. (2008) Functional SNPs in CD244 increase the risk of rheumatoid arthritis in a Japanese population. Nat Genet 40: 1224-1229).
Briefly, human B-lymphoblastoid cell lines immortalized by EBV were obtained from PSC. DNA and RNA were extracted by standard procedures from 22 cell lines that were heterozygous (TC type) for rs2000811 alleles. The amounts of mRNA precursors were compared between alleles using real time PCR probes for SNP typing.
DNA samples from homozygous (CC type and TT type) cell lines were mixed at ratios of 2:1, 3:2, 1:1, 2:3, 1:2, 1:3, 1:4, and 1:6 to draw standard curves for the calculation of RNA quantity.
Joint synovial tissue samples were obtained from 23 RA patients and 5 control patients in Department of Diagnostic Pathology and Department of Orthopaedic Surgery, both in Kyoto University Hospital. The tissue samples were embedded in paraffin and sectioned to give a thickness of 3 μm with standard techniques. Each section was mounted on a glass slide coated with APS. Immunohistochemical staining of MBP was performed by the standard ABC method.
The sections were incubated overnight at 4° C. with a mouse anti-MBP monoclonal antibody diluted at 1:100 in PBS buffer. The sections were then incubated with biotinylated horse anti-mouse IgG antibody for 40 minutes, followed by incubation with peroxidase-conjugated streptavidin at room temperature for 50 minutes.
The coloring reaction was performed with 0.3 mg/ml diaminobenzidine and 0.003% H2O2 dissolved in 50 mM Tris-HCl buffer (pH 7.6).
Each section was counterstained with HE. Evaluation of MBP expression was performed by a blind test by two rheumatologists and a pathologist. The results were analyzed by Fisher's exact test.
The presence or absence of anti-MBP antibodies was examined by ELISA on serum samples from 323 RA patients, 133 healthy controls, and 162 patients with other connective tissue diseases (SLE: 38 cases; Sjögren's syndrome: 25 cases; scleroderma: 25 cases; Behcet's disease: 20 cases; mixed connective tissue disease: 20 cases; dermatomyositis or polymyositis: 19 cases; and vasculitis: 15 cases). As an antigen, a human brain-derived MBP protein (Sigma, St. Louis, Mo.) was used. Further, a recombinant human MBP protein (Genscript, Piscataway, N.J.) was prepared and citrullinated with rabbit skeleton PAD (Sigma, St. Louis, Mo.) (Lundberg K, Kinloch A, Fisher B A, Wegner N, Wait R, et al. (2008) Antibodies to citrullinated alpha-enolase peptide 1 are specific for rheumatoid arthritis and cross-react with bacterial enolase. Arthritis Rheum 58: 3009-3019). The reactivity of autoantibodies was quantified using non-citrullinated recombinant MBP protein and citrullinated recombinant MBP protein.
Four case-control collections totaling 3128 cases and 3044 controls were used for GWAS analysis (Table 2). Markers were selected based on the results of GWAS. As a result, 225,079 markers common to the used chips were judged to have no problem for use in assays. Association analysis was performed on these 225,079 markers. Mean call rate was 99.5% in the 1st collection and 99.8% in the 2nd collection. No lowering of p-value due to stratification of samples was observed (λ=1.03,
Association of MBP Gene Expression with rs2000811
Subsequently, the present inventors examined whether rs2000811-containing sequences might be involved in transcription. DNA and RNA were extracted from immortalized lymphoblastoid cell lines in 22 healthy controls who were heterozygous for rs2000811 alleles, and RNA was reverse transcribed to cDNA. Analysis of allele-specific transcription using the DNA and cDNA revealed that the polymorphism of rs2000811 associated with RA is involved in elevated expression of MBP gene (
When known transcriptional regulatory elements were searched through database, no such element was found in the region containing rs2000811. This region was also found to have comparatively low interspecies conservation among placental mammals.
Inflammation in RA is mainly observed in the joint synovial membrane. The present inventors obtained synovial membrane tissue samples from 23 RA patients and 5 non-RA patients with such diseases as osteoarthritis, and performed immuno-staining with anti-MBP antibodies. The results revealed a highly frequent and strong expression of MBP protein in the synovial membrane of RA patients (
It is known that anti-MBP antibodies play an important role in multiple sclerosis, an autoimmune neurodegenerative disease. The present inventors quantified the anti-MBP antibodies in serum samples obtained from 323 RA patients, 133 healthy controls, and 162 patients with other connective tissue diseases. Anti-MBP antibody titers in RA patients were higher than those in healthy controls and patients with other connective tissue diseases (p<0.001,
In the study described above, the present inventors elucidated the association between RA and a SNP located in the second intron of MBP gene on chromosome 18 by GWAS-based analyses. This SNP was flanked with two relatively weak LD blocks. Determination of the nucleotide sequence of the MBP region revealed that no genetic variation in strong LD with this SNP is present in the exon regions or the promoter region. The present inventors found that expression of MBP gene is associated with this SNP, but failed to show any relationship between this SNP-containing sequence and known transcriptional regulatory elements. For this reason, it is unknown whether rs2000811 per se or a genetic variation in LD with rs2000811 (which could not be found in the study described above) is the cause to alter the expression of MBP gene. Examination of the nucleotide sequence of the 18 kb region between the two LD blocks flanking rs2000811 might elucidate a variation as the true cause. It has not been reported to date that this region is associated with RA in a European population. Since the susceptibility to RA varies greatly depending on race, this region may not be associated in a European population but confirmation of the result for each race is important for understanding the pathology that underlies the disease. MBP is classified into classic MBP which is found in neuronal cells and Golli-MBP which is also found in hematopoietic cells, and rs2000811 is located in the second intron in the Golli-MBP encoding region. Since only a small number of RA cases present with neurologic symptoms, the susceptibility to RA may be associated with Golli-MBP.
Further, the present inventors showed that MBP protein is expressed strongly and at high frequency in the synovial membrane of RA patients. Expression of MBP protein on the cell surface of synovial membrane may be suggesting that anti-MBP antibodies cause inflammation targeting at synovial membrane cells.
The present inventors have also shown that anti-MBP antibodies are RA markers. Many, but not all, of anti-MBP antibodies seem to recognize citrullinated MBP. Although anti-MBP antibodies were not associated with SNPs, some SNPs may be involved in post-translational modifications. The study of the present inventors is the first to show not only the genetic association of MBP with RA but also the expression of MBP gene, the expression of MBP protein, and the occurrence of autoantibodies to MBP.
3.2 × 10−21
9.5 × 10−12
3.6 × 10−31
5.0 × 10−31
All publications, patents and patent applications cited herein are incorporated herein by reference in their entirety.
The present invention is applicable to diagnosis of RA. The present invention is also applicable to screening for substances effective for prevention and/or treatment of RA.
SEQ ID NO: 1 shows a nucleotide sequence of 1602 by comprising the polymorphic site of rs2000811 at position 1102 (y=C/T).
SEQ ID NO: 2 shows a nucleotide sequence of 1001 by comprising the polymorphic site of rs9958028 at position 501 (r=A/G).
| Number | Date | Country | Kind |
|---|---|---|---|
| 2011-095625 | Apr 2011 | JP | national |
| Filing Document | Filing Date | Country | Kind | 371c Date |
|---|---|---|---|---|
| PCT/JP2012/060426 | 4/18/2012 | WO | 00 | 3/4/2014 |
